Literature DB >> 26818499

Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.

Subramanian Rajagopalan1, Anand Rane1, Shankar J Chinta2, Julie K Andersen2.   

Abstract

We previously reported that pharmacological inhibition of a class of enzymes known as prolyl hydroxylase domain proteins (PHDs) has neuroprotective effects in various in vitro and in vivo models of Parkinson's disease (PD). We hypothesized that this was due to inhibition of the PHD2 isoform, preventing it from hydroxylating the transcription factor hypoxia inducible factor 1 α (HIF1α), targeting it for eventual proteasomal degradation. HIF1α itself induces the transcription of various cellular stress genes, including several involved in iron metabolism. Although all three isoforms of PHD are expressed within vulnerable dopaminergic (DAergic) substantia nigra pars compacta neurons, only select downregulation of the PHD2 isoform was found to protect against in vivo neurodegenerative effects associated with the mitochondrial neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. These findings were corroborated in induced pluripotent stem cell-derived neurons, providing validation in a pertinent human cell model. PHD2 inhibition was found to result in increased expression of ATP13A2, mutation of which is responsible for a rare juvenile form of PD known as Kufor-Rakeb syndrome. Knockdown of ATP13A2 expression within human DAergic cells was found to abrogate restoration of cellular iron homeostasis and neuronal cell viability elicited by inhibition of PHD2 under conditions of mitochondrial stress, likely via effects on lysosomal iron storage. These data suggest that regulation of ATP13A2 by the PHD2-HIF1α signaling pathway affects cellular iron homeostasis and DAergic neuronal survival. This constitutes a heretofore unrecognized process associated with loss of ATP13A2 function that could have wide-ranging implications for it as a therapeutic target for PD and other related conditions. SIGNIFICANCE STATEMENT: Reductions in PHD2 activity within dopaminergic neurons in vivo and in cultured human induced pluripotent stem cell-derived neurons protects against mitochondrial stress-induced neurotoxicity. Protective effects are dependent on downstream HIF-1α expression. Knockdown of ATP13A2, a gene linked to a rare juvenile form of Parkinson's disease and recently identified as a novel HIF1α target, was found to abrogate maintenance of cellular iron homeostasis and neuronal viability elicited by PHD2 inhibition in vivo and in cultured dopaminergic cells under conditions of mitochondrial stress. Mechanistically, this was due to ATP13A2's role in maintaining lysosomal iron stores. This constitutes a novel mechanism by which alterations in ATP13A2 activity may be driving PD-related neuropathology.
Copyright © 2016 the authors 0270-6474/16/361086-10$15.00/0.

Entities:  

Keywords:  ATP13A2; MPTP; Parkinson's disease; iron; prolyl hydroxylase domain enzymes; transgenic mice

Mesh:

Substances:

Year:  2016        PMID: 26818499      PMCID: PMC6404282          DOI: 10.1523/JNEUROSCI.3117-15.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  Comparison of mammalian cell lines expressing distinct isoforms of divalent metal transporter 1 in a tetracycline-regulated fashion.

Authors:  Michael D Garrick; Hung-Chieh Kuo; Farida Vargas; Steven Singleton; Lin Zhao; Jaime J Smith; Prasad Paradkar; Jerome A Roth; Laura M Garrick
Journal:  Biochem J       Date:  2006-09-15       Impact factor: 3.857

2.  Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

Authors:  Deepinder Kaur; Ferda Yantiri; Subramanian Rajagopalan; Jyothi Kumar; Jun Qin Mo; Rapee Boonplueang; Veena Viswanath; Russell Jacobs; Lichuan Yang; M Flint Beal; Dino DiMonte; Irene Volitaskis; Lisa Ellerby; Robert A Cherny; Ashley I Bush; Julie K Andersen
Journal:  Neuron       Date:  2003-03-27       Impact factor: 17.173

3.  Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling.

Authors:  Javorina Milosevic; Martina Maisel; Florian Wegner; Julia Leuchtenberger; Roland H Wenger; Manfred Gerlach; Alexander Storch; Johannes Schwarz
Journal:  J Neurosci       Date:  2007-01-10       Impact factor: 6.167

4.  A conserved family of prolyl-4-hydroxylases that modify HIF.

Authors:  R K Bruick; S L McKnight
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

5.  Intralysosomal iron chelation protects against oxidative stress-induced cellular damage.

Authors:  Tino Kurz; Bertil Gustafsson; Ulf T Brunk
Journal:  FEBS J       Date:  2006-06-07       Impact factor: 5.542

6.  Hypoxia induces changes in expression of isoforms of the divalent metal transporter (DMT1) in rat pheochromocytoma (PC12) cells.

Authors:  Agnieszka Lis; Prasad N Paradkar; Steve Singleton; Hung-Chieh Kuo; Michael D Garrick; Jerome A Roth
Journal:  Biochem Pharmacol       Date:  2005-04-22       Impact factor: 5.858

7.  Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.

Authors:  Ambreena Siddiq; Issam A Ayoub; Juan C Chavez; Leila Aminova; Sapan Shah; Joseph C LaManna; Stephanie M Patton; James R Connor; Robert A Cherny; Irene Volitakis; Ashley I Bush; Ingrid Langsetmo; Todd Seeley; Volkmar Gunzler; Rajiv R Ratan
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

8.  Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.

Authors:  Moussa B H Youdim; Galia Stephenson; Dorit Ben Shachar
Journal:  Ann N Y Acad Sci       Date:  2004-03       Impact factor: 5.691

Review 9.  Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases.

Authors:  Silvia Mandel; Orly Weinreb; Tamar Amit; Moussa B H Youdim
Journal:  J Neurochem       Date:  2004-03       Impact factor: 5.372

10.  Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.

Authors:  Steven P Presgraves; Tariq Ahmed; Sabine Borwege; Jeffrey N Joyce
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.978

View more
  19 in total

Review 1.  Parkinson's disease and iron.

Authors:  Hideki Mochizuki; Chi-Jing Choong; Kousuke Baba
Journal:  J Neural Transm (Vienna)       Date:  2020-02-05       Impact factor: 3.575

2.  Missense Variants in HIF1A and LACC1 Contribute to Leprosy Risk in Han Chinese.

Authors:  Dong Wang; Yu Fan; Mahadev Malhi; Rui Bi; Yong Wu; Min Xu; Xiu-Feng Yu; Heng Long; Yu-Ye Li; Deng-Feng Zhang; Yong-Gang Yao
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

3.  A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.

Authors:  Banibrata Das; Subramanian Rajagopalan; Gnanada S Joshi; Liping Xu; Dan Luo; Julie K Andersen; Sokol V Todi; Aloke K Dutta
Journal:  Neuropharmacology       Date:  2017-05-19       Impact factor: 5.250

4.  Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function.

Authors:  Nikhita Anand; Angelina Holcom; Michael Broussalian; Minna Schmidt; Shankar J Chinta; Gordon J Lithgow; Julie K Andersen; Manish Chamoli
Journal:  Neurobiol Dis       Date:  2020-02-05       Impact factor: 5.996

Review 5.  Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  David Devos; Z Ioav Cabantchik; Caroline Moreau; Véronique Danel; Laura Mahoney-Sanchez; Hind Bouchaoui; Flore Gouel; Anne-Sophie Rolland; James A Duce; Jean-Christophe Devedjian
Journal:  J Neural Transm (Vienna)       Date:  2020-01-07       Impact factor: 3.575

Review 6.  The Roles of ATP13A2 Gene Mutations Leading to Abnormal Aggregation of α-Synuclein in Parkinson's Disease.

Authors:  Fan Zhang; Zhiwei Wu; Fei Long; Jieqiong Tan; Ni Gong; Xiaorong Li; Changwei Lin
Journal:  Front Cell Neurosci       Date:  2022-07-06       Impact factor: 6.147

7.  Hsp90 Co-chaperone p23 contributes to dopaminergic mitochondrial stress via stabilization of PHD2: Implications for Parkinson's disease.

Authors:  Anand Rane; Subramanian Rajagopalan; Manuj Ahuja; Bobby Thomas; Shankar J Chinta; Julie K Andersen
Journal:  Neurotoxicology       Date:  2018-02-20       Impact factor: 4.294

8.  Bioactive Flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers - Implications for Parkinson's Disease.

Authors:  Natalya A Smirnova; Navneet Ammal Kaidery; Dmitry M Hushpulian; Ilay I Rakhman; Andrey A Poloznikov; Vladimir I Tishkov; Saravanan S Karuppagounder; Irina N Gaisina; Anton Pekcec; Klaus Van Leyen; Sergey V Kazakov; Lichuan Yang; Bobby Thomas; Rajiv R Ratan; Irina G Gazaryan
Journal:  Aging Dis       Date:  2016-12-01       Impact factor: 6.745

9.  Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson's disease.

Authors:  Dominic J Hare; Bárbara Rita Cardoso; Erika P Raven; Kay L Double; David I Finkelstein; Ewa A Szymlek-Gay; Beverley-Ann Biggs
Journal:  NPJ Parkinsons Dis       Date:  2017-01-05

Review 10.  Targeting iron metabolism in drug discovery and delivery.

Authors:  Bart J Crielaard; Twan Lammers; Stefano Rivella
Journal:  Nat Rev Drug Discov       Date:  2017-02-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.